The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: A randomized controlled trial

British Journal of Dermatology

Volumn 149, Issue 2, 2003, Pages 354-362

  Berger, R S ^a   Fu, J L ^b   Smiles, Kenneth A ^c   Turner, C B ^c   Schnell, B M ^c   Werchowski, K M ^c   Lammers, K M ^c  

^a Hill Top Research Inc   (United States)

^b Reed Hartman Research Center   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Male pattern baldness; Microscopy; Minoxidil; Pyrithione zinc; Randomized controlled trial

Indexed keywords

MINOXIDIL; PYRITHIONE ZINC;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDRUFF; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FIBER OPTICS; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; MICROSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALP HAIR; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALOPECIA; ANALYSIS OF VARIANCE; DRUG THERAPY, COMBINATION; FIBER OPTICS; HAIR; HAIR PREPARATIONS; HUMANS; MALE; MIDDLE AGED; MINOXIDIL; ORGANOMETALLIC COMPOUNDS; PATIENT SATISFACTION; PHOTOGRAPHY; PYRIDINES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0041912418     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05435.x     Document Type: Article

References (17)

1. Brodland DG, Muller SA. Androgenetic alopecia (common baldness). Cutis 1991; 47: 173-6.
2. Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359-65.
3. Pierard GE, Pierard-Franchimont C, Nikkels-Tassoudji N et al. Improvement in the inflammatory aspect of androgenetic alopecia: a pilot study with an antimicrobiai lotion. J Dermatol Treat 1996; 7: 153-7.
4. Pierard-Franchimont C, De Daricker P, Cauwenbergh G et al. Ketoconazole shampoo: effect of long-term use in androgenetic alopecia. Dermatology 1998; 196: 474-7.
5. Tenenbaum S, Opdyke D. Antimicrobiai properties of antiseborrheic agents. Toilet Goods Assoc 1967; 47: 20-3.
6. United States Government Code of Federal Resolutions, Title 21, Volume 5, Part 358, Subpart H. Drug Products for the Control of Dandruff. Seborrheic Dermatitis and Psoriasis. Sections 358. 710-750, pp 302-303. Revised as of 1 April 2002.
7. Hamilton J. Patterned loss of hair in man: types and incidence. Ann NY Acad Sci 1951; 53: 708-28.
8. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Control Clin Trials 1991; 12 (Suppl.): 142S-58S.
9. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 713-21.
10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-2.
11. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
12. Sueki H. Stoudemayer T, Kligman AM et al. Quantitative and ultra-structural analysis of inflammatory infiltrates in male pattern alopecia. Acta Derm Venereol (Stockh) 1999; 79: 347-50.
13. Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol 1992; 127: 239-46.
14. Young JW, Conte ET, Leavitt ML et al. Cutaneous immunopathology of androgenetic alopecia. J Am Osteopath Assoc 1991; 91: 765-71.
15. Gueniche A, Viac J, Lizard G et al. Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol (Stockh) 1995; 75: 19-23.
16. Rostan EF, DeBuys HV, Madey DL, Pinnell SR. Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol 2002; 41: 606-11.
17. Stamatiadis D, Bulteau-Protois MC. Inhibition of 5 alpha reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 119: 627-32.